Omnicell Inc is a healthcare technology company that specializes in streamlining medication management and supply chain solutions for pharmacies and healthcare facilities. The company develops automated systems and software that enhance the efficiency of medication dispensing, inventory management, and patient safety. By offering a comprehensive suite of products, including automated dispensing cabinets, central pharmacy automation, and cloud-based analytics, Omnicell aims to improve the operational workflows of healthcare providers, reduce medication errors, and ultimately enhance patient care. Their innovative solutions are designed to meet the evolving needs of the healthcare industry, supporting successful medication therapies and optimizing pharmacy operations. Read More
Omnicell’s first quarter was marked by strong execution and operational improvements, leading to results that exceeded Wall Street’s expectations. Management...
Omnicell, Inc. (Nasdaq:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, announced that it will present at the BofA Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8:40 a.m. PDT.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell” or the “Company”), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Rick Couldry has joined the Company as Senior Vice President, Chief Pharmacy and Clinical Officer.
Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 14.9% year on year to $30...
Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 14.9% year on year to $3...
Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” or the “Company”), a leading healthcare technology provider focused on empowering autonomous medication management, today reported financial results for the first quarter ended March 31, 2026.
Healthcare tech company Omnicell (NASDAQ:OMCL) will be announcing earnings results this Tuesday before market hours. Here’s what to look for. Omnicell met an...
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Omnicell (NASDAQ:OMCL) and it...
Omnicell, Inc. (Nasdaq:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the first quarter 2026, before market open on Tuesday, April 28, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
AINewsWire Editorial Coverage : As regulatory expectations intensify and manufacturing complexity grows, pharmaceutical companies are moving beyond traditional quality systems toward a new paradigm: embedding artificial intelligence (“AI”) directly into operations as a real-time compliance layer. Rather than relying on retrospective audits and manual oversight, AI-driven systems now continuously monitor, validate and optimize production processes to align with evolving Good Manufacturing Practice (“GMP”) standards. This structural shift is increasingly visible across the industry and aligns with companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ), which operate at the intersection of life sciences and advanced digital technologies, reflecting the broader movement toward intelligent, automated compliance frameworks. With its focus on AI, Oncotelic joins other AI-focused entities, including NVIDIA Corp. (NASDAQ: NVDA), Amazon.com Inc. (NASDAQ: AMZN), Honeywell International Inc. (NASDAQ: HON) and Omnicell Inc. (NASDAQ: OMCL), that are leading…
AUSTIN, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: As regulatory expectations intensify and manufacturing complexity grows, pharmaceutical companies are moving beyond traditional quality systems toward a new paradigm: embedding artificial intelligence (AI) directly into operations as a real-time compliance layer. Rather than relying on retrospective audits and manual oversight, AI-driven systems now continuously monitor, validate and optimize production processes to align with evolving Good Manufacturing Practice (GMP) standards. This structural shift is increasingly visible across the industry and aligns with companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), which operate at the intersection of life sciences and advanced digital technologies, reflecting the broader movement toward intelligent, automated compliance frameworks. With its focus on AI, Oncotelic joins other AI-focused entities, including NVIDIA Corp. (NASDAQ: NVDA), Amazon.com Inc. (NASDAQ: AMZN), Honeywell International Inc. (NASDAQ: HON) and Omnicell Inc. (NASDAQ: OMCL), that are leading out in the space.
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Over the past six months, Omnicell has been a great trade, beating the S&P 500 by 19.8%. Its stock price has climbed to $41.48, representing a healthy 26.4% ...
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
